Cork, Ireland, February 2023 – Metabolomic Diagnostics is delighted to share our most recent publication in the American Journal of Obstetrics and Gynecology, First-trimester preterm preeclampsia prediction with metabolite biomarkers: differential prediction according to maternal body mass index.
Written in association with Professor Nicolaides (King’s College Hospital, London, United Kingdom), the highlighted study ”aimed to verify metabolite biomarkers as first-trimester predictors for preterm preeclampsia (PE) and to investigate the interaction of biomarker prediction with maternal body mass index (BMI)”.
The findings of differential biomarker prediction according to body mass index support the existence of different maternal risk profiles (with associated biomarkers) in which preeclampsia develops via different pathophysiological pathways. Those complex pathways open new possibilities in preeclampsia risk assessment and classification.
You can read the paper here or on the Science Direct website.